Tempus AI had its Relative Strength (RS) Rating upgraded from 69 to 90 Tuesday.
Here Are 3 Keys For Successful Stock Investing
IBD's proprietary RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matches up against all other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners typically have an RS Rating north of 80 as they begin their biggest runs.
While Tempus AI is not near a proper entry right now, see if it manages to form and break out of a proper chart pattern.
Tempus AI posted 0% earnings growth last quarter. Revenue increased 75%.
Tempus AI earns the No. 6 rank among its peers in the Medical-Research Equipment/Services industry group. Fulgent Genetics, Tempus AI and Medpace Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
